Estudo de coorte | Impacto do status baixo vs. negativo do receptor de estrogênio/progesterona sobre as características clínico-patológicas e os desfechos de sobrevida no câncer de mama HER2-negativo.
10 Ago, 2022 | 14:10h
Comentário no Twitter
Out on NPJ Breast a new report on #ERlowtumors. No difference in characteristics, pCR rates, RFS os OS compared with #TNBC. Patients with ER-low tumors should be treated as for TNBC. Also, important confounder to remember in HER2-low prognostic analyses.https://t.co/M1GF8eyYbT pic.twitter.com/CrLyUgyhUV
— Paolo Tarantino (@PTarantinoMD) July 11, 2022